Wnt Signaling as a Therapeutic Target for Cancer

  • Andreas Herbst
  • Frank Thomas Kolligs
Part of the Methods in Molecular Biology™ book series (MIMB, volume 361)


The Wnt/β-catenin signaling pathway is tightly regulated and has important functions in development, tissue homeostasis, and regeneration. Deregulation of Wnt/β-catenin signaling is frequently found in various human cancers. Eighty percent of colorectal cancers alone reveal activation of this pathway by either inactivation of the tumor-suppressor gene adenomatous polyposis coli or mutation of the proto-oncogene β-catenin. Activation of Wnt/β-catenin signaling has been found to be important for both initiation and progression of cancers of different tissues. Therefore, targeted inhibition of Wnt/β-catenin signaling is a rational and promising new approach for the therapy of cancers of various origins.

Key Words

Wnt signalling adenomatous polyposis coli APC β-catenin Tcf LEF targeted therapy small molecules antisense siRNA RNAi 


  1. 1.
    Ross, J. S., Schenkein, D. P., Pietrusko, R., et al. (2004) Targeted therapies for cancer 2004. Am. J. Clin. Pathol. 122, 598–609.PubMedGoogle Scholar
  2. 2.
    Jordan, V. C. (2003) Tamoxifen: a most unlikely pioneering medicine. Nat. Rev. Drug Discov. 2, 205–213.PubMedGoogle Scholar
  3. 3.
    McKeage, K. and Perry, C. M. (2002) Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 62, 209–243.PubMedGoogle Scholar
  4. 4.
    Reynolds, N. A. and Wagstaff, A. J. (2004) Cetuximab: in the treatment of metastatic colorectal cancer. Drugs 64, 109–121.PubMedGoogle Scholar
  5. 5.
    McCarthy, M. (2003) Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet 361, 1959.PubMedGoogle Scholar
  6. 6.
    Sparano, J. A., Gray, R., Giantonio, B., O’Dwyer, P., and Comis, R. L. (2004) Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials. Clin. Cancer Res. 10, 1206–1211.PubMedGoogle Scholar
  7. 7.
    Goldman, J. M. and Melo, J. V. (2003) Chronic myeloid leukemia—advances in biology and new approaches to treatment. N. Engl. J. Med. 349, 1451–1464.PubMedGoogle Scholar
  8. 8.
    von Mehren, M. (2003) Gastrointestinal stromal tumors: a paradigm for molecularly targeted therapy. Cancer Invest. 21, 553–563.Google Scholar
  9. 9.
    Druker, B. J. (2003) Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert Opin. Pharmacother. 4, 963–971.PubMedGoogle Scholar
  10. 10.
    Verweij, J., van Oosterom, A., Blay, J. Y., et al. (2003) Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur. J. Cancer 39, 2006–2011.PubMedGoogle Scholar
  11. 11.
    Dean, N. M. and Bennett, C. F. (2003) Antisense oligonucleotide-based therapeutics for cancer. Oncogene 22, 9087–9096.PubMedGoogle Scholar
  12. 12.
    Wang, H., Prasad, G., Buolamwini, J. K., and Zhang, R. (2001) Antisense anticancer oligonucleotide therapeutics. Curr. Cancer Drug Targets 1, 177–196.PubMedGoogle Scholar
  13. 13.
    Jansen, B., Wacheck, V., Heere-Ress, E., et al. (2000) Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356, 1728–1733.PubMedGoogle Scholar
  14. 14.
    Chi, K. N., Gleave, M. E., Klasa, R., et al. (2001) A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin. Cancer Res. 7, 3920–3927.PubMedGoogle Scholar
  15. 15.
    Iversen, P. L., Arora, V., Acker, A. J., Mason, D. H., and Devi, G. R. (2003) Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin. Cancer Res. 9, 2510–2519.PubMedGoogle Scholar
  16. 16.
    Advani, R., Peethambaram, P., Lum, B. L., et al. (2004) A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer 100, 321–326.PubMedGoogle Scholar
  17. 17.
    Niemann, S., Zhao, C., Pascu, F., et al. (2004) Homozygous WNT3 mutation causes tetra-amelia in a large consanguineous family. Am. J. Hum. Genet. 74, 558–563.PubMedGoogle Scholar
  18. 18.
    Jordan, B. K., Shen, J. H., Olaso, R., Ingraham, H. A., and Vilain, E. (2003) Wnt4 overexpression disrupts normal testicular vasculature and inhibits testosterone synthesis by repressing steroidogenic factor 1/beta-catenin synergy. Proc. Natl. Acad. Sci. USA 100, 10,866–10,871.PubMedGoogle Scholar
  19. 19.
    Rodova, M., Islam, M. R., Maser, R. L., and Calvet, J. P. (2002) The polycystic kidney disease-1 promoter is a target of the beta-catenin/T-cell factor pathway. J. Biol. Chem. 277, 29,577–29,583.PubMedGoogle Scholar
  20. 20.
    Robitaille, J., MacDonald, M. L., Kaykas, A., et al. (2002) Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy. Nat. Genet. 32, 326–330.PubMedGoogle Scholar
  21. 21.
    Toomes, C., Bottomley, H. M., Jackson, R. M., et al. (2004) Mutations in LRP5 or FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q. Am. J. Hum. Genet. 74, 721–730.PubMedGoogle Scholar
  22. 22.
    Lammi, L., Arte, S., Somer, M., et al. (2004) Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am. J. Hum. Genet. 74, 1043–1050.PubMedGoogle Scholar
  23. 23.
    Kim, J. S., Crooks, H., Foxworth, A., and Waldman, T. (2002) Proof-of-principle: oncogenic beta-catenin is a valid molecular target for the development of pharmacological inhibitors. Mol. Cancer Ther. 1, 1355–1359.PubMedGoogle Scholar
  24. 24.
    Gunther, E. J., Moody, S. E., Belka, G. K., et al. (2003) Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev. 17, 488–501.PubMedGoogle Scholar
  25. 25.
    Derksen, P. W., Tjin, E., Meijer, H. P., et al. (2004) Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc. Natl. Acad. Sci. USA 101, 6122–6127.PubMedGoogle Scholar
  26. 26.
    Rijsewijk, F., Schuermann, M., Wagenaar, E., Parren, P., Weigel, D., and Nusse, R. (1987) The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless. Cell 50, 649–657.PubMedGoogle Scholar
  27. 27.
    Cadigan, K. M. and Nusse, R. (1997) Wnt signaling: a common theme in animal development. Genes Dev. 11, 3286–3305.PubMedGoogle Scholar
  28. 28.
    Papkoff, J., Rubinfeld, B., Schryver, B., and Polakis, P. (1996) Wnt-1 regulates free pools of catenins and stabilizes APC-catenin complexes. Mol. Cell. Biol. 16, 2128–2134.PubMedGoogle Scholar
  29. 29.
    Polakis, P. (2000) Wnt signaling and cancer. Genes Dev. 14, 1837–1851.PubMedGoogle Scholar
  30. 30.
    Veeman, M. T., Axelrod, J. D., and Moon, R. T. (2003) A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling. Dev. Cell. 5, 367–377.PubMedGoogle Scholar
  31. 31.
    Mann, B., Gelos, M., Siedow, A., et al. (1999) Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc. Natl. Acad. Sci. USA 96, 1603–1608.PubMedGoogle Scholar
  32. 32.
    Xia, Y. and Karin, M. (2004) The control of cell motility and epithelial morphogenesis by Jun kinases. Trends Cell Biol. 14, 94–101.PubMedGoogle Scholar
  33. 33.
    Wada, T. and Penninger, J. M. (2004) Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23, 2838–2849.PubMedGoogle Scholar
  34. 34.
    Kennedy, N. J. and Davis, R. J. (2003) Role of JNK in tumor development. Cell Cycle 2, 199–201.PubMedGoogle Scholar
  35. 35.
    Miller, J. R. (2002) The Wnts. Genome Biol 3, REVIEWS3001.Google Scholar
  36. 36.
    Huang, H. C. and Klein, P. S. (2004) The Frizzled family: receptors for multiple signal transduction pathways. Genome Biol. 5, 234.PubMedGoogle Scholar
  37. 37.
    Tamai, K., Semenov, M., Kato, Y., et al. (2000) LDL-receptor-related proteins in Wnt signal transduction. Nature 407, 530–535.PubMedGoogle Scholar
  38. 38.
    Jones, S. E. and Jomary, C. (2002) Secreted Frizzled-related proteins: searching for relationships and patterns. Bioessays 24, 811–820.PubMedGoogle Scholar
  39. 39.
    Hsieh, J. C., Kodjabachian, L., Rebbert, M. L., et al. (1999) A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 398, 431–436.PubMedGoogle Scholar
  40. 40.
    Brott, B. K. and Sokol, S. Y. (2002) Regulation of Wnt/LRP signaling by distinct domains of Dickkopf proteins. Mol. Cell. Biol. 22, 6100–6110.PubMedGoogle Scholar
  41. 41.
    Fedi, P., Bafico, A., Nieto Soria, A., et al. (1999) Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. J. Biol. Chem. 274, 19,465–19,472.PubMedGoogle Scholar
  42. 42.
    Mao, B., Wu, W., Li, Y., et al. (2001) LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 411, 321–325.PubMedGoogle Scholar
  43. 43.
    Mao, B., Wu, W., Davidson, G., et al. (2002) Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 417, 664–667.PubMedGoogle Scholar
  44. 44.
    Barth, A. I., Nathke, I. S., and Nelson, W. J. (1997) Cadherins, catenins and APC protein: interplay between cytoskeletal complexes and signaling pathways. Curr. Opin. Cell. Biol. 9, 683–690.PubMedGoogle Scholar
  45. 45.
    Graham, N. A. and Asthagiri, A. R. (2004) Epidermal growth factor-mediated T-cell factor/lymphoid enhancer factor transcriptional activity is essential but not sufficient for cell cycle progression in nontransformed mammary epithelial cells. J. Biol. Chem. 279, 23,517–23,524.PubMedGoogle Scholar
  46. 46.
    Danilkovitch-Miagkova, A., Miagkov, A., Skeel, A., Nakaigawa, N., Zbar, B., and Leonard, E. J. (2001) Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway. Mol. Cell. Biol. 21, 5857–5868.PubMedGoogle Scholar
  47. 47.
    Bonvini, P., An, W. G., Rosolen, A., et al. (2001) Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription. Cancer Res. 61, 1671–1677.PubMedGoogle Scholar
  48. 48.
    Hinoi, T., Yamamoto, H., Kishida, M., Takada, S., Kishida, S., and Kikuchi, A. (2000) Complex formation of adenomatous polyposis coli gene product and axin facilitates glycogen synthase kinase-3 beta-dependent phosphorylation of beta-catenin and down-regulates beta-catenin. J. Biol. Chem. 275, 34,399–34,406.PubMedGoogle Scholar
  49. 49.
    Ikeda, S., Kishida, M., Matsuura, Y., Usui, H., and Kikuchi, A. (2000) GSK-3beta-dependent phosphorylation of adenomatous polyposis coli gene product can be modulated by beta-catenin and protein phosphatase 2A complexed with Axin. Oncogene 19, 537–545.PubMedGoogle Scholar
  50. 50.
    Yamamoto, H., Kishida, S., Kishida, M., Ikeda, S., Takada, S., and Kikuchi, A. (1999) Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3beta regulates its stability. J. Biol. Chem. 274, 10,681–10,684.PubMedGoogle Scholar
  51. 51.
    Kishida, S., Yamamoto, H., Ikeda, S., et al. (1998) Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of beta-catenin. J. Biol. Chem. 273, 10,823–10,826.PubMedGoogle Scholar
  52. 52.
    Ikeda, S., Kishida, S., Yamamoto, H., Murai, H., Koyama, S., and Kikuchi, A. (1998) Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. Embo. J. 17, 1371–1384.PubMedGoogle Scholar
  53. 53.
    Liu, C., Li, Y., Semenov, M., Han, C., et al. (2002) Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108, 837–847.PubMedGoogle Scholar
  54. 54.
    Amit, S., Hatzubai, A., Birman, Y., et al. (2002) Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev. 16, 1066–1076.PubMedGoogle Scholar
  55. 55.
    Latres, E., Chiaur, D. S., and Pagano, M. (1999) The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin. Oncogene 18, 849–854.PubMedGoogle Scholar
  56. 56.
    Hart, M., Concordet, J. P., Lassot, I., et al. (1999) The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr. Biol. 9, 207–210.PubMedGoogle Scholar
  57. 57.
    Aberle, H., Bauer, A., Stappert, J., Kispert, A., and Kemler, R. (1997) beta-catenin is a target for the ubiquitin-proteasome pathway. Embo J. 16, 3797–3804.PubMedGoogle Scholar
  58. 58.
    Kishida, M., Hino, S., Michiue, T., et al. (2001) Synergistic activation of the Wnt signaling pathway by Dvl and casein kinase Iepsilon. J. Biol. Chem. 276, 33,147–33,155.PubMedGoogle Scholar
  59. 59.
    Lee, E., Salic, A., and Kirschner, M. W. (2001) Physiological regulation of [beta]-catenin stability by Tcf3 and CK1epsilon. J. Cell. Biol. 154, 983–993.PubMedGoogle Scholar
  60. 60.
    Mao, J., Wang, J., Liu, B., et al. (2001) Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol. Cell. 7, 801–809.PubMedGoogle Scholar
  61. 61.
    Matsuzawa, S. I. and Reed, J. C. (2001) Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol. Cell. 7, 915–926.PubMedGoogle Scholar
  62. 62.
    Liu, J., Stevens, J., Rote, C. A., et al. (2001) Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol. Cell. 7, 927–936.PubMedGoogle Scholar
  63. 63.
    Sadot, E., Geiger, B., Oren, M., and Ben-Ze’ev, A. (2001) Down-regulation of beta-catenin by activated p53. Mol. Cell. Biol. 21, 6768–6781.PubMedGoogle Scholar
  64. 64.
    Behrens, J., von Kries, J. P., Kuhl, M., et al. (1996) Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 382, 638–642.PubMedGoogle Scholar
  65. 65.
    Molenaar, M., van de Wetering, M., Oosterwegel, M., et al. (1996) XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell 86, 391–399.PubMedGoogle Scholar
  66. 66.
    Cavallo, R. A., Cox, R. T., Moline, M. M., et al. (1998) Drosophila Tcf and Groucho interact to repress Wingless signalling activity. Nature 395, 604–608.PubMedGoogle Scholar
  67. 67.
    Roose, J., Molenaar, M., Peterson, J., et al. (1998) The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors. Nature 395, 608–612.PubMedGoogle Scholar
  68. 68.
    Brantjes, H., Barker, N., van Es, J., and Clevers, H. (2002) TCF: Lady Justice casting the final verdict on the outcome of Wnt signalling. Biol. Chem. 383, 255–261.PubMedGoogle Scholar
  69. 69.
    Hecht, A., Vleminckx, K., Stemmler, M. P., van Roy, F., and Kemler, R. (2000) The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. Embo. J. 19, 1839–1850.PubMedGoogle Scholar
  70. 70.
    Sun, Y., Kolligs, F. T., Hottiger, M. O., Mosavin, R., Fearon, E. R., and Nabel, G. J. (2000) Regulation of beta-catenin transformation by the p300 transcriptional coactivator. Proc. Natl. Acad. Sci. USA 97, 12,613–12,618.PubMedGoogle Scholar
  71. 71.
    Takemaru, K. I. and Moon, R. T. (2000) The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. J. Cell. Biol. 149, 249–254.PubMedGoogle Scholar
  72. 72.
    Barker, N., Hurlstone, A., Musisi, H., Miles, A., Bienz, M., and Clevers, H. (2001) The chromatin remodelling factor Brg-1 interacts with beta-catenin to promote target gene activation. Embo. J. 20, 4935–4943.PubMedGoogle Scholar
  73. 73.
    Bauer, A., Huber, O., and Kemler, R. (1998) Pontin52, an interaction partner of beta-catenin, binds to the TATA box binding protein. Proc. Natl. Acad. Sci. USA 95, 14,787–14,792.PubMedGoogle Scholar
  74. 74.
    He, T. C., Sparks, A. B., Rago, C., et al. (1998) Identification of c-MYC as a target of the APC pathway. Science 281, 1509–1512.PubMedGoogle Scholar
  75. 75.
    Shtutman, M., Zhurinsky, J., Simcha, I., et al. (1999) The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. USA 96, 5522–5527.PubMedGoogle Scholar
  76. 76.
    Tetsu, O. and McCormick, F. (1999) Beta-catenin regulates expression of cyclin D1in colon carcinoma cells. Nature 398, 422–426.PubMedGoogle Scholar
  77. 77.
    Zhang, X., Gaspard, J. P., and Chung, D. C. (2001) Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res. 61, 6050–6054.PubMedGoogle Scholar
  78. 78.
    Brabletz, T., Jung, A., Dag, S., Hlubek, F., and Kirchner, T. (1999) beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am. J. Pathol. 155, 1033–1038.PubMedGoogle Scholar
  79. 79.
    Takahashi, M., Tsunoda, T., Seiki, M., Nakamura, Y., and Furukawa, Y. (2002) Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin/Tcf4 complex in human colorectal cancers. Oncogene 21, 5861–5867.PubMedGoogle Scholar
  80. 80.
    Marchenko, N. D., Marchenko, G. N., Weinreb, R. N., et al. (2004) Beta-catenin regulates the gene of MMP-26, a novel metalloproteinase expressed both in carcinomas and normal epithelial cells. Int. J. Biochem. Cell. Biol. 36, 942–956.PubMedGoogle Scholar
  81. 81.
    van der Heyden, M. A., Rook, M. B., Hermans, M. M., et al. (1998) Identification of connexin43 as a functional target for Wnt signalling. J. Cell. Sci. 111, 1741–1749.PubMedGoogle Scholar
  82. 82.
    He, T. C., Chan, T. A., Vogelstein, B., and Kinzler, K. W. (1999) PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99, 335–345.PubMedGoogle Scholar
  83. 83.
    Kolligs, F. T., Nieman, M. T., Winer, I., et al. (2002) ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation. Cancer Cell. 1, 145–155.PubMedGoogle Scholar
  84. 84.
    Blache, P., van de Wetering, M., Duluc, I., et al. (2004) SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J. Cell. Biol. 166, 37–47.PubMedGoogle Scholar
  85. 85.
    Saitoh, T., Mine, T., and Katoh, M. (2002) Frequent up-regulation of WNT5A mRNA in primary gastric cancer. Int. J. Mol. Med. 9, 515–519.PubMedGoogle Scholar
  86. 86.
    Rhee, C. S., Sen, M., Lu, D., et al. (2002) Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas. Oncogene 21, 6598–6605.PubMedGoogle Scholar
  87. 87.
    Holcombe, R. F., Marsh, J. L., Waterman, M. L., Lin, F., Milovanovic, T., and Truong, T. (2002) Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma. Mol. Pathol. 55, 220–226.PubMedGoogle Scholar
  88. 88.
    Lu, D., Zhao, Y., Tawatao, R., et al. (2004) Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 101, 3118–3123.PubMedGoogle Scholar
  89. 89.
    Tanaka, S., Akiyoshi, T., Mori, M., Wands, J. R., and Sugimachi, K. (1998) A novel frizzled gene identified in human esophageal carcinoma mediates APC/beta-catenin signals. Proc. Natl. Acad. Sci. USA 95, 10,164–10,169.PubMedGoogle Scholar
  90. 90.
    Kirikoshi, H., Sekihara, H., and Katoh, M. (2001) Up-regulation of Frizzled-7 (FZD7) in human gastric cancer. Int. J. Oncol. 19, 111–115.PubMedGoogle Scholar
  91. 91.
    Hoang, B. H., Kubo, T., Healey, J. H., et al. (2004) Expression of LDL receptorrelated protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int. J. Cancer 109, 106–111.PubMedGoogle Scholar
  92. 92.
    Nagahata, T., Shimada, T., Harada, A., et al. (2003) Amplification, up-regulation and over-expression of DVL-1, the human counterpart of the Drosophila disheveled gene, in primary breast cancers. Cancer Sci. 94, 515–518.PubMedGoogle Scholar
  93. 93.
    Okino, K., Nagai, H., Hatta, M., et al. (2003) Up-regulation and overproduction of DVL-1, the human counterpart of the Drosophila dishevelled gene, in cervical squamous cell carcinoma. Oncol. Rep. 10, 1219–1223.PubMedGoogle Scholar
  94. 94.
    Uematsu, K., Kanazawa, S., You, L., et al. (2003) Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res. 63, 4547–4551.PubMedGoogle Scholar
  95. 95.
    Saitoh, T. and Katoh, M. (2001) FRAT1 and FRAT2, clustered in human chromosome 10q24.1 region, are up-regulated in gastric cancer. Int. J. Oncol. 19, 311–315.PubMedGoogle Scholar
  96. 96.
    Ugolini, F., Charafe-Jauffret, E., Bardou, V. J., et al. (2001) WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene 20, 5810–5817.PubMedGoogle Scholar
  97. 97.
    Stoehr, R., Wissmann, C., Suzuki, H., et al. (2004) Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab. Invest. 84, 465–478.PubMedGoogle Scholar
  98. 98.
    Suzuki, H., Watkins, D. N., Jair, K. W., et al. (2004) Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet. 36, 417–422.PubMedGoogle Scholar
  99. 99.
    Lee, A. Y., He, B., You, L., et al. (2004) Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene 23, 6672–6676.PubMedGoogle Scholar
  100. 100.
    Wissmann, C., Wild, P. J., Kaiser, S., et al. (2003) WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J. Pathol. 201, 204–212.PubMedGoogle Scholar
  101. 101.
    Mazieres, J., He, B., You, L., et al. (2004) Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res. 64, 4717–4720.PubMedGoogle Scholar
  102. 102.
    He, B., Lee, A. Y., Dadfarmay, S., et al. (2005) Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells. Cancer Res. 65, 743–748.PubMedGoogle Scholar
  103. 103.
    Satoh, S., Daigo, Y., Furukawa, Y., et al. (2000) AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat. Genet. 24, 245–250.PubMedGoogle Scholar
  104. 104.
    Taniguchi, K., Roberts, L. R., Aderca, I. N., et al. (2002) Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 21, 4863–4871.PubMedGoogle Scholar
  105. 105.
    Liu, W., Dong, X., Mai, M., et al. (2000) Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat. Genet. 26, 146–147.PubMedGoogle Scholar
  106. 106.
    Dahmen, R. P., Koch, A., Denkhaus, D., et al. (2001) Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res. 61, 7039–7043.PubMedGoogle Scholar
  107. 107.
    Yokota, N., Nishizawa, S., Ohta, S., et al. (2002) Role of Wnt pathway in medulloblastoma oncogenesis. Int. J. Cancer 101, 198–201.PubMedGoogle Scholar
  108. 108.
    Groden, J., Thliveris, A., Samowitz, W., et al. (1991) Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66, 589–600.PubMedGoogle Scholar
  109. 109.
    Nishisho, I., Nakamura, Y., Miyoshi, Y., et al. (1991) Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253, 665–669.PubMedGoogle Scholar
  110. 110.
    Miyoshi, Y., Nagase, H., Ando, H., et al. (1992) Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum. Mol. Genet. 1, 229–233.PubMedGoogle Scholar
  111. 111.
    Lamlum, H., Ilyas, M., Rowan, A., et al. (1999) The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson’s ‘two-hit’ hypothesis. Nat. Med. 5, 1071–1075.PubMedGoogle Scholar
  112. 112.
    Rowan, A. J., Lamlum, H., Ilyas, M., et al. (2000) APC mutations in sporadic colorectal tumors: A mutational “hotspot” and interdependence of the “two hits.” Proc. Natl. Acad. Sci. USA 97, 3352–3357.PubMedGoogle Scholar
  113. 113.
    Su, L. K., Vogelstein, B., and Kinzler, K. W. (1993) Association of the APC tumor suppressor protein with catenins. Science 262, 1734–1737.PubMedGoogle Scholar
  114. 114.
    Rubinfeld, B., Albert, I., Porfiri, E., Munemitsu, S., and Polakis, P. (1997) Loss of beta-catenin regulation by the APC tumor suppressor protein correlates with loss of structure due to common somatic mutations of the gene. Cancer Res. 57, 4624–4630.PubMedGoogle Scholar
  115. 115.
    Hart, M. J., de los Santos, R., Albert, I. N., Rubinfeld, B., and Polakis, P. (1998) Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr. Biol. 8, 573–581.PubMedGoogle Scholar
  116. 116.
    Rubinfeld, B., Albert, I., Porfiri, E., Fiol, C., Munemitsu, S., and Polakis, P. (1996) Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 272, 1023–1026.PubMedGoogle Scholar
  117. 117.
    Rubinfeld, B., Souza, B., Albert, I., et al. (1993) Association of the APC gene product with beta-catenin. Science 262, 1731–1734.PubMedGoogle Scholar
  118. 118.
    Munemitsu, S., Albert, I., Souza, B., Rubinfeld, B., and Polakis, P. (1995) Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc. Natl. Acad. Sci. USA 92, 3046–3050.PubMedGoogle Scholar
  119. 119.
    Behrens, J., Jerchow, B. A., Wurtele, M., et al. (1998) Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 280, 596–599.PubMedGoogle Scholar
  120. 120.
    Peifer, M., Pai, L. M., and Casey, M. (1994) Phosphorylation of the Drosophila adherens junction protein Armadillo: roles for wingless signal and zeste-white 3 kinase. Dev. Biol. 166, 543–556.PubMedGoogle Scholar
  121. 121.
    Kawahara, K., Morishita, T., Nakamura, T., Hamada, F., Toyoshima, K., and Akiyama, T. (2000) Down-regulation of beta-catenin by the colorectal tumor suppressor APC requires association with Axin and beta-catenin. J. Biol. Chem. 275, 8369–8374.PubMedGoogle Scholar
  122. 122.
    Kinzler, K. W. and Vogelstein, B. (1996) Lessons from hereditary colorectal cancer. Cell 87, 159–170.PubMedGoogle Scholar
  123. 123.
    Reifenberger, J., Knobbe, C. B., Wolter, M., et al. (2002) Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC. Int. J. Cancer 100, 549–556.PubMedGoogle Scholar
  124. 124.
    Koch, A., Waha, A., Tonn, J. C., et al. (2001) Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. Int. J. Cancer 93, 445–449.PubMedGoogle Scholar
  125. 125.
    Huang, H., Mahler-Araujo, B. M., Sankila, A., et al. (2000) APC mutations in sporadic medulloblastomas. Am. J. Pathol. 156, 433–437.PubMedGoogle Scholar
  126. 126.
    Tejpar, S., Nollet, F., Li, C., et al. (1999) Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 18, 6615–6620.PubMedGoogle Scholar
  127. 127.
    Alman, B. A., Li, C., Pajerski, M. E., Diaz-Cano, S., and Wolfe, H. J. (1997) Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am. J. Pathol. 151, 329–334.PubMedGoogle Scholar
  128. 128.
    Sparks, A. B., Morin, P. J., Vogelstein, B., and Kinzler, K. W. (1998) Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 58, 1130–1134.PubMedGoogle Scholar
  129. 129.
    Morin, P. J., Sparks, A. B., Korinek, V., et al. (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275, 1787–1790.PubMedGoogle Scholar
  130. 130.
    Kitaeva, M. N., Grogan, L., Williams, J. P., et al. (1997) Mutations in beta-catenin are uncommon in colorectal cancer occurring in occasional replication error-positive tumors. Cancer Res. 57, 4478–4481.PubMedGoogle Scholar
  131. 131.
    Iwao, K., Nakamori, S., Kameyama, M., et al. (1998) Activation of the beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. Cancer Res. 58, 1021–1026.PubMedGoogle Scholar
  132. 132.
    Mirabelli-Primdahl, L., Gryfe, R., Kim, H., et al. (1999) Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res. 59, 3346–3351.PubMedGoogle Scholar
  133. 133.
    Wong, C. M., Fan, S. T., and Ng, I. O. (2001) beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 92, 136–145.PubMedGoogle Scholar
  134. 134.
    Koch, A., Denkhaus, D., Albrecht, S., Leuschner, I., von Schweinitz, D., and Pietsch, T. (1999) Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res. 59, 269–273.PubMedGoogle Scholar
  135. 135.
    Park, W. S., Oh, R. R., Park, J. Y., et al. (1999) Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res. 59, 4257–4260.PubMedGoogle Scholar
  136. 136.
    Clements, W. M., Wang, J., Sarnaik, A., et al. (2002) beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res. 62, 3503–3506.PubMedGoogle Scholar
  137. 137.
    Fujimori, M., Ikeda, S., Shimizu, Y., Okajima, M., and Asahara, T. (2001) Accumulation of beta-catenin protein and mutations in exon 3 of beta-catenin gene in gastrointestinal carcinoid tumor. Cancer Res. 61, 6656–6659.PubMedGoogle Scholar
  138. 138.
    Abraham, S. C., Nobukawa, B., Giardiello, F. M., Hamilton, S. R., and Wu, T. T. (2001) Sporadic fundic gland polyps: common gastric polyps arising through activating mutations in the beta-catenin gene. Am. J. Pathol. 158, 1005–1010.PubMedGoogle Scholar
  139. 139.
    Abraham, S. C., Wu, T. T., Hruban, R. H., et al. (2002) Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am. J. Pathol. 160, 953–962.PubMedGoogle Scholar
  140. 140.
    Abraham, S. C., Klimstra, D. S., Wilentz, R. E., et al. (2002) Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am. J. Pathol. 160, 1361–1369.PubMedGoogle Scholar
  141. 141.
    Gamallo, C., Palacios, J., Moreno, G., Calvo de Mora, J., Suarez, A., and Armas, A. (1999) beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am. J. Pathol. 155, 527–536.Google Scholar
  142. 142.
    Wu, R., Zhai, Y., Fearon, E. R., and Cho, K. R. (2001) Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res. 61, 8247–8255.PubMedGoogle Scholar
  143. 143.
    Fukuchi, T., Sakamoto, M., Tsuda, H., Maruyama, K., Nozawa, S., and Hirohashi, S. (1998) Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res. 58, 3526–3528.PubMedGoogle Scholar
  144. 144.
    Kobayashi, K., Sagae, S., Nishioka, Y., Tokino, T., and Kudo, R. (1999) Mutations of the beta-catenin gene in endometrial carcinomas. Jpn. J. Cancer Res. 90, 55–59.PubMedGoogle Scholar
  145. 145.
    Garcia-Rostan, G., Camp, R. L., Herrero, A., Carcangiu, M. L., Rimm, D. L., and Tallini, G. (2001) Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am. J. Pathol. 158, 987–996.PubMedGoogle Scholar
  146. 146.
    Voeller, H. J., Truica, C. I., and Gelmann, E. P. (1998) Beta-catenin mutations in human prostate cancer. Cancer Res. 58, 2520–2523.PubMedGoogle Scholar
  147. 147.
    Chesire, D. R., Ewing, C. M., Sauvageot, J., Bova, G. S., and Isaacs, W. B. (2000) Detection and analysis of beta-catenin mutations in prostate cancer. Prostate 45, 323–334.PubMedGoogle Scholar
  148. 148.
    Zurawel, R. H., Chiappa, S. A., Allen, C., and Raffel, C. (1998) Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res. 58, 896–899.PubMedGoogle Scholar
  149. 149.
    Koesters, R., Niggli, F., von Knebel Doeberitz, M., and Stallmach, T. (2003) Nuclear accumulation of beta-catenin protein in Wilms’ tumours. J. Pathol. 199, 68–76.Google Scholar
  150. 150.
    Giles, R. H., van Es, J. H., and Clevers, H. (2003) Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta 1653, 1–24.PubMedGoogle Scholar
  151. 151.
    Kim, J. S., Crooks, H., Foxworth, A., and Waldman, T. (2002) Proof-of-principle: oncogenic beta-catenin is a valid molecular target for the development of pharmacological inhibitors. Mol. Cancer Ther. 1, 1355–1359.PubMedGoogle Scholar
  152. 152.
    Tsuji, T., Nozaki, I., Miyazaki, M., et al. (2001) Antiproliferative activity of REIC/Dkk-3 and its significant down-regulation in non-small-cell lung carcinomas. Biochem. Biophys. Res. Commun. 289, 257–263.PubMedGoogle Scholar
  153. 153.
    Hoang, B. H., Kubo, T., Healey, J. H., et al. (2004) Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res. 64, 2734–2739.PubMedGoogle Scholar
  154. 154.
    Shou, J., Ali-Osman, F., Multani, A. S., Pathak, S., Fedi, P., and Srivenugopal, K. S. (2002) Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. Oncogene 21, 878–889.PubMedGoogle Scholar
  155. 155.
    He, B., You, L., Uematsu, K., et al. (2004) A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 6, 7–14.PubMedGoogle Scholar
  156. 156.
    He, B., Reguart, N., You, L., et al. (2005) Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 24, 3054–3058.PubMedGoogle Scholar
  157. 157.
    Suzuki, H., Gabrielson, E., Chen, W., et al. (2002) A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet. 31, 141–149.PubMedGoogle Scholar
  158. 158.
    Caldwell, G. M., Jones, C., Gensberg, K., et al. (2004) The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res. 64, 883–888.PubMedGoogle Scholar
  159. 159.
    Roh, H., Green, D. W., Boswell, C. B., Pippin, J. A., and Drebin, J. A. (2001) Suppression of beta-catenin inhibits the neoplastic growth of APC-mutant colon cancer cells. Cancer Res. 61, 6563–6568.PubMedGoogle Scholar
  160. 160.
    Green, D. W., Roh, H., Pippin, J. A., and Drebin, J. A. (2001) Beta-catenin antisense treatment decreases beta-catenin expression and tumor growth rate in colon carcinoma xenografts. J. Surg. Res. 101, 16–20.PubMedGoogle Scholar
  161. 161.
    Choi, Y. W., Heath, E. I., Heitmiller, R., Forastiere, A. A., and Wu, T. T. (2000) Mutations in beta-catenin and APC genes are uncommon in esophageal and esophagogastric junction adenocarcinomas. Mod. Pathol. 13, 1055–1059.PubMedGoogle Scholar
  162. 162.
    Wijnhoven, B. P., Dinjens, W. N., and Pignatelli, M. (2000) E-cadherin-catenin cell-cell adhesion complex and human cancer. Br. J. Surg. 87, 992–1005.PubMedGoogle Scholar
  163. 163.
    Chung, E. J., Hwang, S. G., Nguyen, P., et al. (2002) Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. Blood 100, 982–990.PubMedGoogle Scholar
  164. 164.
    van de Wetering, M., Oving, I., Muncan, V., et al. (2003) Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep. 4, 609–615.PubMedGoogle Scholar
  165. 165.
    Verma, U. N., Surabhi, R. M., Schmaltieg, A., Becerra, C., and Gaynor, R. B. (2003) Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin. Cancer Res. 9, 1291–1300.PubMedGoogle Scholar
  166. 166.
    Soutschek, J., Akinc, A., Bramlage, B., et al. (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173–178.PubMedGoogle Scholar
  167. 167.
    Rossi, J. J. (2004) Medicine: a cholesterol connection in RNAi. Nature 432, 155–156.PubMedGoogle Scholar
  168. 168.
    Morin, P. J., Vogelstein, B., and Kinzler, K. W. (1996) Apoptosis and APC in colorectal tumorigenesis. Proc. Natl. Acad. Sci. USA 93, 7950–7954.PubMedGoogle Scholar
  169. 169.
    Shih, I. M., Yu, J., He, T. C., Vogelstein, B., and Kinzler, K. W. (2000) The beta-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression. Cancer Res. 60, 1671–1676.PubMedGoogle Scholar
  170. 170.
    Cong, F., Schweizer, L., Chamorro, M., and Varmus, H. (2003) Requirement for a nuclear function of beta-catenin in Wnt signaling. Mol. Cell. Biol. 23, 8462–8470.PubMedGoogle Scholar
  171. 171.
    Su, Y., Ishikawa, S., Kojima, M., and Liu, B. (2003) Eradication of pathogenic beta-catenin by Skp1/Cullin/F box ubiquitylation machinery. Proc. Natl. Acad. Sci. USA 100, 12,729–12,734.PubMedGoogle Scholar
  172. 172.
    Liu, J., Stevens, J., Matsunami, N., and White, R. L. (2004) Targeted degradation of beta-catenin by chimeric F-box fusion proteins. Biochem. Biophys. Res. Commun. 313, 1023–1029.PubMedGoogle Scholar
  173. 173.
    Papkoff, J. and Aikawa, M. (1998) WNT-1 and HGF regulate GSK3 beta activity and beta-catenin signaling in mammary epithelial cells. Biochem. Biophys. Res. Commun. 247, 851–858.PubMedGoogle Scholar
  174. 174.
    Playford, M. P., Bicknell, D., Bodmer, W. F., and Macaulay, V. M. (2000) Insulinlike growth factor 1regulates the location, stability, and transcriptional activity of beta-catenin. Proc. Natl. Acad. Sci. USA 97, 12,103–12,108.PubMedGoogle Scholar
  175. 175.
    Piedra, J., Martinez, D., Castano, J., Miravet, S., Dunach, M., and de Herreros, A. G. (2001) Regulation of beta-catenin structure and activity by tyrosine phosphorylation. J. Biol. Chem. 276, 20,436–20,443.PubMedGoogle Scholar
  176. 176.
    Vlahovic, G. and Crawford, J. (2003) Activation of tyrosine kinases in cancer. Oncologist 8, 531–538.PubMedGoogle Scholar
  177. 177.
    Lu, Z., Ghosh, S., Wang, Z., and Hunter, T. (2003) Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell. 4, 499–515.PubMedGoogle Scholar
  178. 178.
    Lu, Z. and Hunter, T. (2004) Wnt-independent beta-catenin transactivation in tumor development. Cell Cycle 3, 571–573.PubMedGoogle Scholar
  179. 179.
    Zhou, L., An, N., Haydon, R. C., et al. (2003) Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity. Cancer Lett. 193, 161–170.PubMedGoogle Scholar
  180. 180.
    Chen, R. H. and McCormick, F. (2001) Selective targeting to the hyperactive beta-catenin/T-cell factor pathway in colon cancer cells. Cancer Res. 61, 4445–4449.PubMedGoogle Scholar
  181. 181.
    Kwong, K. Y., Zou, Y., Day, C. P., and Hung, M. C. (2002) The suppression of colon cancer cell growth in nude mice by targeting beta-catenin/TCF pathway. Oncogene 21, 8340–8346.PubMedGoogle Scholar
  182. 182.
    Ring, C. J. (2002) Cytolytic viruses as potential anti-cancer agents. J. Gen. Virol. 83, 491–502.PubMedGoogle Scholar
  183. 183.
    Brunori, M., Malerba, M., Kashiwazaki, H., and Iggo, R. (2001) Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway. J. Virol. 75, 2857–2865.PubMedGoogle Scholar
  184. 184.
    Fuerer, C. and Iggo, R. (2002) Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway. Gene Ther. 9, 270–281.PubMedGoogle Scholar
  185. 185.
    Toth, K., Djeha, H., Ying, B., et al. (2004) An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated wnt signaling. Cancer Res. 64, 3638–3644.PubMedGoogle Scholar
  186. 186.
    Malerba, M., Daeffler, L., Rommelaere, J., and Iggo, R. D. (2003) Replicating parvoviruses that target colon cancer cells. J. Virol. 77, 6683–6691.PubMedGoogle Scholar
  187. 187.
    Lepourcelet, M., Chen, Y. N., France, D. S., et al. (2004) Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 5, 91–102.PubMedGoogle Scholar
  188. 188.
    Emami, K. H., Nguyen, C., Ma, H., et al. (2004) A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc. Natl. Acad. Sci. USA 101, 12,682–12,687.PubMedGoogle Scholar
  189. 189.
    Dang, C. V. (1999) c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol. 19, 1–11.PubMedGoogle Scholar
  190. 190.
    Whittaker, S. R., Walton, M. I., Garrett, M. D., and Workman, P. (2004) the Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogenactivated protein kinase pathway. Cancer Res. 64, 262–272.PubMedGoogle Scholar
  191. 191.
    Hidalgo, M. and Rowinsky, E. K. (2000) The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19, 6680–6686.PubMedGoogle Scholar
  192. 192.
    Suto, R., Tominaga, K., Mizuguchi, H., et al. (2004) Dominant-negative mutant of c-Jun gene transfer: a novel therapeutic strategy for colorectal cancer. Gene Ther. 11, 187–193.PubMedGoogle Scholar
  193. 193.
    Easwaran, V., Lee, S. H., Inge, L., et al. (2003) beta-Catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res. 63, 3145–3153.PubMedGoogle Scholar
  194. 194.
    Gupta, R. A. and DuBois, R. N. (2000) Translational studies on Cox-2 inhibitors in the prevention and treatment of colon cancer. Ann. NY Acad. Sci. 910, 196–204.PubMedGoogle Scholar
  195. 195.
    Araki, Y., Okamura, S., Hussain, S. P., et al. (2003) Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res. 63, 728–734.PubMedGoogle Scholar
  196. 196.
    Dimberg, J., Hugander, A., Sirsjo, A., and Soderkvist, P. (2001) Enhanced expression of cyclooxygenase-2 and nuclear beta-catenin are related to mutations in the APC gene in human colorectal cancer. Anticancer Res. 21, 911–915.PubMedGoogle Scholar
  197. 197.
    Thun, M. J., Henley, S. J., and Patrono, C. (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 94, 252–266.PubMedGoogle Scholar
  198. 198.
    Koehne, C. H. and Dubois, R. N. (2004) COX-2 inhibition and colorectal cancer. Semin. Oncol. 31, 12–21.PubMedGoogle Scholar
  199. 199.
    Oshima, M. and Taketo, M. M. (2002) COX selectivity and animal models for colon cancer. Curr. Pharm. Des. 8, 1021–1034.PubMedGoogle Scholar
  200. 200.
    Ricchi, P., Palma, A. D., Matola, T. D., et al. (2003) Aspirin protects Caco-2 cells from apoptosis after serum deprivation through the activation of a phosphatidylinositol 3-kinase/AKT/p21Cip/WAF1pathway. Mol. Pharmacol. 64, 407–414.PubMedGoogle Scholar
  201. 201.
    Lew, J. I., Guo, Y., Kim, R. K., Vargish, L., Michelassi, F., and Arenas, R. B. (2002) Reduction of intestinal neoplasia with adenomatous polyposis coli gene replacement and COX-2 inhibition is additive. J. Gastrointest. Surg. 6, 563–568.PubMedGoogle Scholar
  202. 202.
    Kielman, M. F., Rindapaa, M., Gaspar, C., et al. (2002) Apc modulates embryonic stem-cell differentiation by controlling the dosage of beta-catenin signaling. Nat. Genet. 32, 594–605.PubMedGoogle Scholar
  203. 203.
    Reya, T., Duncan, A. W., Ailles, L., et al. (2003) A role for Wnt signalling in selfrenewal of haematopoietic stem cells. Nature 423, 409–414.PubMedGoogle Scholar
  204. 204.
    Sato, N., Meijer, L., Skaltsounis, L., Greengard, P., and Brivanlou, A. H. (2004) Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat. Med. 10, 55–63.PubMedGoogle Scholar
  205. 205.
    Korinek, V., Barker, N., Moerer, P., et al. (1998) Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat. Genet. 19, 379–383.PubMedGoogle Scholar
  206. 206.
    van de Wetering, M., Sancho, E., Verweij, C., et al. (2002) The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111, 241–250.PubMedGoogle Scholar
  207. 207.
    Chan, T. A., Wang, Z., Dang, L. H., Vogelstein, B., and Kinzler, K. W. (2002) Targeted inactivation of CTNNB1 reveals unexpected effects of beta-catenin mutation. Proc. Natl. Acad. Sci. USA 99, 8265–8270.PubMedGoogle Scholar
  208. 208.
    Kim, S. J., Im, D. S., Kim, S. H., et al. (2002) Beta-catenin regulates expression of cyclooxygenase-2 in articular chondrocytes. Biochem. Biophys. Res. Commun. 296, 221–226.PubMedGoogle Scholar
  209. 209.
    Willert, K., Brown, J. D., Danenberg, E., et al. (2003) Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 423, 448–452.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Andreas Herbst
    • 1
    • 2
  • Frank Thomas Kolligs
    • 1
    • 2
  1. 1.Clinical Research Unit for Gastrointestinal CancersLudwig-Maximilians-UniversityMunichGermany
  2. 2.Department of Medicine II, Klinikum GrosshadernLudwig-Maximilians-UniversityMunichGermany

Personalised recommendations